๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Relapsed Neuroblastoma

Study in Children and Adolescents of 177Lu-DOTATATE (Lutatheraยฎ) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). NCT06607692Phase 1, Phase 21 site๐Ÿ“ Boadilla del Monte Fundaciรณn de investigaciรณn HM ยท Tests: Olaparib; 177Lu-DOTATATE Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma NCT06995872Phase 11 site๐Ÿ“ Bethesda National Cancer Institute (NCI) ยท Tests: rhIL-15, Dinituximab, Temozolomide, Irinotecan Hydrochloride NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial NCT06450041Phase 213 sites๐Ÿ“ Los Angeles๐Ÿ“ San Francisco๐Ÿ“ Aurora New Approaches to Neuroblastoma Therapy Consortium ยท Tests: Universal Donor (UD) TGFฮฒi NK Cells, Temozolomide, Irinotecan, Dinutuximab, GM-CSF NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma NCT07211737Phase 11 site๐Ÿ“ Houston Baylor College of Medicine ยท Tests: i15.NKG2D.zeta NK cells and C7R.GD2.CARTs cells, i15.NKG2D.zeta NK cells and C7R.GD2.CARTs cells, i15.NKG2D.zeta NK celโ€ฆ Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse NCT07437963Phase 1, Phase 22 sites๐Ÿ“ Oakland๐Ÿ“ Chicago National Cancer Institute (NCI) ยท Tests: Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Dinutuximab Immunotherapy With Dinutuximab Beta in Combination With Chemotherapy for the Treatment of Patients With Primary Neuroblastoma Refractory to Standard Therapy and With Relapsed or Progressive Disease NCT05272371Phase 11 site๐Ÿ“ Krakow Jagiellonian University ยท Tests: Chemoimmunotherapy (Dinutuximab beta in combination with chemotherapy) Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma NCT06540963Phase 212 sites๐Ÿ“ Little Rock๐Ÿ“ Hartford๐Ÿ“ Miami Giselle Sholler ยท Tests: Tipifarnib, Naxitamab Haploidentical Donor Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Neuroblastoma NCT07635056Phase 21 site๐Ÿ“ Cincinnati Children's Hospital Medical Center, Cincinnati ยท Tests: CIML-NK Cells Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma NCT03721068Phase 12 sites๐Ÿ“ Atlanta๐Ÿ“ Chapel Hill UNC Lineberger Comprehensive Cancer Center ยท Tests: iC9.GD2.CAR.IL-15 T-cells, Cyclophosphamide, Fludarabine Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors NCT07584499Phase 11 site๐Ÿ“ Guangzhou Sun Yat-sen University ยท Tests: Becotatug Vedotin B7-H3.CD28Z.CART in Solid Tumors NCT07358260Phase 11 site๐Ÿ“ Boston Robbie Majzner ยท Tests: B7-H3.CD28Z.CART, Fludarabine, Cyclophosphamide A Multi-Arm, Platform Trial For Relapsed Neuroblastoma NCT07334301Phase 1, Phase 223 sites๐Ÿ“ Sydney๐Ÿ“ Vienna๐Ÿ“ Brussels University of Birmingham ยท Tests: Bevacizumab, Dinutuximab beta, Irinotecan (drug), Topotecan, Temozolomide (TMZ) Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma NCT00107289Phase 21 site๐Ÿ“ New York Memorial Sloan Kettering Cancer Center ยท Tests: iobenguane I 131 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma NCT04903899Phase 25 sites๐Ÿ“ Copenhagen๐Ÿ“ Vilnius๐Ÿ“ Utrecht Jakob Stenman ยท Tests: 177Lu-DOTATATE Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma NCT07502287Phase 1, Phase 21 site๐Ÿ“ Shenzhen Beijing Biotech ยท Tests: EB-DTNB-NK, Fludarabine, Cyclophosphamide A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory Neuroblastoma NCT07085338Phase 25 sites๐Ÿ“ San Francisco๐Ÿ“ Aurora๐Ÿ“ Ann Arbor St. Jude Children's Research Hospital ยท Tests: Temozolomide, Irinotecan, hu14.18K322A, N803, Sargramostim Quadruple Immunotherapy for Neuroblastoma NCT05754684Phase 21 site๐Ÿ“ Hong Kong Hong Kong Children's Hospital ยท Tests: Natural killer cell, Dinutuximab beta, Interleukin-2, Granulocyte-Macrophage Colony-Stimulating Factor, Spironolactone Reduced Intensity Haploidentical BMT for High Risk Solid Tumors NCT01804634Phase 23 sites๐Ÿ“ Baltimore๐Ÿ“ The Bronx๐Ÿ“ Valhalla Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins ยท Tests: Cyclophosphamide, Fludarabine, low dose total body irradiation, Melphalan, Tacrolimus Safety, Tolerability, and Preliminary Efficacy of [211At]MABG in Patients With Relapsed or Refractory Neuroblastoma NCT07767630EARLY Phase 11 site๐Ÿ“ Chengdu Sichuan University ยท Tests: [211At]MABG Serial ctDNA and Molecular Residual Disease Monitoring in Neuroblastoma NCT07516678n/a1 site๐Ÿ“ Guangzhou Sun Yat-sen University PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors NCT06721689Phase 1, Phase 27 sites๐Ÿ“ Los Angeles๐Ÿ“ San Francisco๐Ÿ“ Boston Theodore Laetsch ยท Tests: PEEL-224, Vincristine, Temozolomide (TMZ) Phase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastoma in Children NCT07318831Phase 21 site๐Ÿ“ Tianjin Tianjin Medical University Cancer Institute and Hospital ยท Tests: Chidamide Combined with Dinutuximab Beta, Irinotecan, and Temozolomide Chemoimmunotherapy Combined With Autologous NK Cell Therapy for Pediatric Patients With Refractory and Relapsed High-Risk Neuroblastoma and Ganglioneuroblastoma NCT07375563Phase 31 site๐Ÿ“ Moscow Federal Research Institute of Pediatric Hematology, Oncologโ€ฆ ยท Tests: Dinutuximab beta, temozolomide, irinotecan, autologous NK cell, irinotecan, temozolomide, dinutuximab beta, NK-cell proโ€ฆ Safety and Efficacy of CAR-T Cell Therapy for Relapsed/refractory Neuroblastoma and Desmoplastic Small Round Cell Tumors: a Single-arm, Open-label Trial. NCT06836505Phase 1, Phase 23 sites๐Ÿ“ Guangzhou๐Ÿ“ Dongguan๐Ÿ“ Shanghai Sun Yat-Sen University Cancer Center ยท Tests: CART therapy Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma NCT05400603Phase 11 site๐Ÿ“ Atlanta Emory University ยท Tests: Ex Vivo Expanded Allogeneic ฮณฮด T Cells in Combination with Dinutuximab, Temozolomide, Irinotecan and Zoledronate Safety and Efficacy of Systemic Allogenic NK Cells in R/R Neuroblastoma NCT06674265Phase 11 site๐Ÿ“ Tehran Marzieh Ebrahimi ยท Tests: Allogenic NK cells infusion Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma NCT04901702Phase 1, Phase 210 sites๐Ÿ“ Palo Alto๐Ÿ“ Aurora๐Ÿ“ Washington D.C. St. Jude Children's Research Hospital ยท Tests: Onivyde, Talazoparib, Temozolomide Chimeric Natural Killer Receptor-Universal T Cells for Relapsed or Refractory Neuroblastoma NCT06751134Phase 12 sites๐Ÿ“ Nanjing๐Ÿ“ Nanjing Nanjing Children's Hospital ยท Tests: Chimeric Natural Killer Receptor Universal T-cells (CNK-UT) Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas NCT06465199Phase 1, Phase 214 sites๐Ÿ“ Birmingham๐Ÿ“ Little Rock๐Ÿ“ Hartford Milton S. Hershey Medical Center ยท Tests: Eflornithine (DFMO), AMXT 1501 Dicaprate Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma NCT07027748Phase 12 sites๐Ÿ“ Boston๐Ÿ“ Boston Steven DuBois, MD ยท Tests: Naxitamab, Irinotecan, Temozolomide, Sargramostim granulocyte-macrophage colony stimulating factor
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy